adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
pharma · Idiopathic Hypersomnia · Prader-Willi Syndrome · HRMY
Harmony Biosciences Holdings
Harmony Biosciences Holdings drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US HQ
2017 Founded
332 Employees
Public company Type
HRMY · NYSE Ticker
Company details
- Status
- Public
- HQ
- 630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US
- Founded
- 2017
- Employees
- 332
- Programs
- 21
- Drugs
- 14
- Patents
- 6
Harmony Biosciences Holdings pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Harmony Biosciences Holdings drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Surfactant agent.
- Mechanism
- Surfactant agent
-
cannabidiol
Nervous system (N03)US regulatory status: approved. Molecular target: Cannabinoid receptor 1.
- Target
- Cannabinoid receptor 1
- Mechanism
- Cannabinoid CB1 receptor negative allosteric modulator
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Harmony Biosciences Holdings's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Harmony Biosciences Holdings's portfolio.
-
Development asset linked to Harmony Biosciences Holdings in public FDA and regional records.
-
pitolisant
Nervous system (N07)US regulatory status: approved. Molecular target: Histamine H3 receptor.
- Target
- Histamine H3 receptor
- Mechanism
- Histamine H3 receptor inverse agonist
-
US regulatory status: approved. Molecular target: Histamine H3 receptor.
- Target
- Histamine H3 receptor
- Mechanism
- Histamine H3 receptor inverse agonist
-
Development asset linked to Harmony Biosciences Holdings in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to Harmony Biosciences Holdings in public FDA and regional records.
-
Development asset linked to Harmony Biosciences Holdings in public FDA and regional records.
-
Development asset linked to Harmony Biosciences Holdings in public FDA and regional records.
-
Development asset linked to Harmony Biosciences Holdings in public FDA and regional records.